Led by postdoc Abhimanyu Amarnani, new work suggests that using antibiotics to target the Ruminococcus gnavus lipoglycan, or the TLR2 protein it activates, could serve as an alternative to current lupus nephritis therapies that suppress the immune system.
nyulangone.org/news/raised-...
nyulangone.org
NYU Langone Health study shows that increased levels of a toxic molecule may serve as a marker of who is most at risk of developing lupus nephritis. Learn more.
